{"id":"917b496394e6","type":"article","url":"https://hartvaat.nl/2026/02/28/onbeantwoorde-vragen-over-lipoproteine-a-en-atherosclerose/","title":"Onbeantwoorde vragen over lipoproteïne(a) en atherosclerose","title_en":"","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":["atherosclerose","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie-screening","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","niet-statine-therapie","pelacarsen","statines"],"journal":"Circulation journal : official journal of the Japanese Circulation Society","doi":"10.1253/circj.CJ-26-0036","source_url":"https://doi.org/10.1253/circj.CJ-26-0036","authors":["Hayato Tada","Masayuki Takamura"],"significance":5,"published":"2026-04-02","source_date":"2026-02-28","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This review discusses unresolved questions regarding the relationship between lipoprotein(a) and atherosclerotic cardiovascular risk. Despite growing evidence for Lp(a) as an independent risk factor, questions remain about therapeutic thresholds and the efficacy of targeted treatment.","created":"2026-07-03T10:32:41Z","updated":"2026-07-03T13:31:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit overzichtsartikel bespreekt de nog openstaande vragen over de relatie tussen lipoproteïne(a) en atherosclerotisch cardiovasculair risico. Ondanks groeiend bewijs voor Lp(a) als onafhankelijke risicofactor, blijven er vragen over therapeutische drempels en de effectiviteit van gerichte behandeling.","abstract_original":""}